Stoke Therapeutics, Inc. (STOK) on Monday said its Chief Financial Officer Stephen Tulipano is stepping down with effect from May 7.In his place, the company has appointed Thomas Leggett as the new finance chief. Prior to joining Stoke, Leggett served as CFO of Affinia Therapeutics. Earlier, he had served as CFO of Black Diamond Therapeutics and Axcella Health.

斯托克治疗公司（STOK）周一表示，其首席财务官斯蒂芬·图利帕诺（StephenTulipano）将于5月7日辞职。该公司已任命托马斯·莱格特（ThomasLeggett）为新任财务总监。在加入斯托克城之前，莱格特曾担任Affinia Therapeutics的首席财务官。此前，他曾担任Black Diamond Therapeutics和Axcella Health的首席财务官。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股